Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole

Phase 1 Completed 24 enrolled Seoul National University Hospital

Non-randomizedParallel-groupOpen-labelBasic science

Summary

A clinical trial to investigate the influence of CYP2C19 polymorphism on pharmacokinetic/pharmacodynamic characteristics of omeprazole in healthy Korean volunteers

Timeline

Start: 2014-09
Primary completion: 2014-12
Completion: —

Publications

Park S, Hyun YJ, Kim YR, Lee JH, Ryu S, Kim JM, Oh WY, Na HS, Lee JG, Seo DW, Hwang IY, Park Z, Jang IJ, Oh J, Choi SE. Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers. J Korean Med Sci. 2017 May;32(5):729-736. doi: 10.3346/jkms.2017.32.5.729.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Omeprazole	Other / unclassified	20 mg	Oral

Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole

Summary

Timeline

Publications

Drugs

Indications